UNSPSC 51332855: Levomepromazine hydrochloride

This classification denotes a cns stimulant with the molecular formula C19H24N2OS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42BB1Y2586, chemically known as 10h-phenothiazine-10-propanamine, 2-methoxy-n,n,beta-trimethyl-, monohydrochloride, (r)- (9ci) but more generally known as levomepromazine hydrochloride, which bears US NIH Compound Identifier 102583. European Medicines Agency schedules Levomepromazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02908MIG.

UNSPSC 51332855 Levomepromazine hydrochloride is a Commodity code that nominally covers a specific pharmaceutical active ingredient, but recent state and local solicitations under this code show little direct activity aligned with that narrow chemical designation. Instead, the posted opportunities frame pharmaceutical procurement at the state and local level as broad acquisitions of multi-source generic drugs, over-the-counter products, naloxone, and pharmacy benefit management services rather than single-ingredient compounds. State and local issuers posting under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The scope of work spans standing contracts for generic pharmaceutical distribution through authorized wholesalers, ad-hoc procurements of specific medications (such as naloxone for opioid response), and exploratory market-intelligence gathering around direct-to-manufacturer pharmacy programs.

Recent activity appears concentrated in Florida and Minnesota, with Texas also active in preliminary market research. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, with responses due March 26, 2026, for multi-year contracts covering generic pharmaceuticals and OTC products distributed to state and local facilities across participating jurisdictions including Oregon; evaluation weights 75 percent to price competitiveness, with vendors required to maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson) and comply with cGMP and Drug Supply Chain Security Act standards. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The Texas Health and Human Services Commission posted Request for Information HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program operating outside traditional pharmacy benefit manager arrangements. The code shows limited direct relevance to levomepromazine hydrochloride specifically and serves primarily as a broad pharmaceutical-procurement classification under which state and local buyers solicit generic drugs, OTC products, and pharmacy services through multistate cooperatives and county health programs.